Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma.
Jonathan S. Cebon
Employment or Leadership Position - Ludwig Institute for Cancer Research
Research Funding - Ludwig Institute for Cancer Research
Grant A. McArthur
No relevant relationships to disclose
Weisan Chen
Research Funding - Ludwig Institute for Cancer Research (B)
Ian D. Davis
Research Funding - Ludwig Institute for Cancer Research
Martin Eric Gore
No relevant relationships to disclose
John F Thompson
No relevant relationships to disclose
Michael Millward
No relevant relationships to disclose
Michael P. N. Findlay
No relevant relationships to disclose
Rod Dunbar
No relevant relationships to disclose
Christian H.H Ottensmeier
No relevant relationships to disclose
Ralph Rudolph Venhaus
Employment or Leadership Position - Ludwig Institute for Cancer Research
Paul D. Nathan
No relevant relationships to disclose
Angus George Dalgleish
Consultant or Advisory Role - Ludwig Institute for Cancer Research
Vincenzo Cerundolo
No relevant relationships to disclose
Eugene Maraskovsky
Employment or Leadership Position - CSL Limited
Stock Ownership - CSL Limited
Wendie Hopkins
No relevant relationships to disclose
Jeremy Marsden
No relevant relationships to disclose
B Mark Smithers
No relevant relationships to disclose
Peter Hersey
No relevant relationships to disclose
T.R. Jeffry Evans
No relevant relationships to disclose